Clinical trials for better health policies

©Mario Beauregard/Fotolia.com

A recent OECD Recommendation on the Governance of Clinical Trials issued in December 2012 could improve the outlook for fighting deadly diseases around the world. Here is how.

Chronic myelogenous leukemia (CML) is a rare cancer that affects the bone marrow. Until ten years ago, a diagnosis of CML was a death sentence unless you had a tissue-matched donor, usually a sibling, and underwent a bone marrow transplant. In 1996, laboratory scientists showed that a drug selectively killed CML cells in culture without harming normal cells. Two years later, the first reports of 31 patients treated with this drug were published; all had dramatic responses.

This impressive progress changed the outlook for these patients, and it could not have been made without clinical trials. And with life expectancy rising around the world, but haunted by the prospect of substantial disability, such clinical trials are likely to become more important in the years ahead. But they are not without their challenges.

Recently the OECD adopted a policy initiative on the governance of clinical trials in an attempt to define a new framework for better oversight of clinical trials, with a special emphasis on facilitating those trials that have public and charitable rather than industry funders.* Why was the instrument adopted and what can it help to achieve?

A tale of two studies

Clinical trials are rigorously designed experiments in which participants who have consented to receive a new therapy or to be assigned randomly to one of several possible treatments are carefully studied for the positive and negative effects of those therapies. The aim is to provide sufficient evidence to guide medical practice and public health policy. Clinical trials are a critical step for the production of new drugs and for the study of existing health treatments. They improve the health and quality of life of our citizens, add value to our economies, and guide policymakers responsible for laws and regulations. This benefit applies to both common and rare diseases.

Take the promising results related to CML again. Over the subsequent five years, multiple studies confirmed the efficacy of the drug, now called Gleevec™. In 2013, bone marrow transplantation is rarely required for patients with CML, whose extended survival is expected. How did this happen? University medical scientists supported by US taxpayer funds from the National Institutes of Health (NIH) worked with a pharmaceutical company, Novartis, to take this drug from the shelf to the clinic. Now patients all over the world receive Gleevec™. Its approval came about because of rigorously conducted clinical trials in which participants with CML agreed to receive an experimental, untested drug. They took significant risks because no one knew whether the drug would work or have bad side effects. Later trials have included Gleevec™ as one of multiple therapies; participants are taking much less risk because the effects of the drugs are now well-known. But because CML is rare, international studies were essential to carry out the test on enough patients to get significant results.

More common diseases also benefit from clinical trials. About the same time that Gleevec™ studies began, 3,234 healthy people at high risk of developing type 2 diabetes agreed to take part in a clinical trial to see if their diabetes could be prevented. A third of the patients had no treatment, a third received an approved marketed anti-diabetes drug called metformin, and the remaining third were put on diet and exercise programmes. Four years later, the people who changed their diet and took exercise were found to be only half as likely to develop diabetes as those with no treatment. Metformin reduced the likelihood of developing diabetes, but also provided less benefit than diet and exercise. The study was funded by US taxpayers and conducted at 27 different sites.

Worldwide, about 370 million people have type 2 diabetes; the WHO estimates that this will rise to 552 million by 2030. Could the results of the US study apply elsewhere, in Germany and the UK, or India and South Africa, for instance? Clinical trials in these countries could help us find out.

The question is, how can we harmonise approaches and better compare results for better policies? Every country has laws and regulations governing the conduct of clinical trials. Following the Second World War, all nations adopted some basic principles to guide the ethical conduct of research. International guidelines are detailed in the Nuremberg Code and the Declaration of Helsinki, while many countries have additional reports, such as the Belmont Report in the US, that outline common principles (see references). These are codified and implemented differently in different countries and regions, but the common principles apply in all countries.

While research studies may pose risks to participants, failure to conduct research poses much greater risks to citizens everywhere. Examples of treatments introduced without enough evidence include thalidomide, which caused disastrous birth defects in infants when given to pregnant women; administration of high doses of oxygen to premature infants with consequent blindness; and the use first of radical mastectomy and, later, of bone marrow transplantation for breast cancer, with major toxicity and no benefit.

Because of differences in laws and regulations, there are often barriers to conducting international research. Regulations designed to assign responsibility for protection of participants and ensure accountability may hinder collaboration. Not all clinical trials pose similar risks to participants. Treatments that are untested may create significant risks to participants and liability for sponsors. In contrast, trials of established therapies (as in the case of the diabetes study described above) pose little or no risk to participants. Existing regulatory systems often have similar administrative requirements whatever the risk, and sponsor liability may be significant.

What is the new OECD Recommendation about? Health care systems and clinical research infrastructure vary widely, especially between high income and lower income countries. Many policy barriers to conducting international trials may exist, many deriving from inconsistencies in definitions, assignment of responsibilities and requirements for oversight. The OECD initiative is a major step towards developing a harmonised framework for the governance of clinical trials. It introduces a risk-based oversight and management methodology, which combines risk categories based on the marketing authorisation status of the medical product with a trial-specific approach that considers issues such as the type of populations involved in a trial, and the informed consent of the patients.

In other words, besides facilitating the conduct of international trials, the implementation of the OECD Recommendation helps to streamline procedures for low-risk trials, while at the same time strengthening the protection of the patients, increasing the quality of the data and improving the credibility of the results. It also addresses the thorny challenge of seeking an accepted method for assessing the risk that participants face in entering a trial, and hence the responsibility borne by the study sponsor for compensation and care of participants affected by the study.

In this together

In December 2012, The Lancet published an entire issue on the Global Burden of Disease Study, demonstrating improved life expectancy with substantial disability for the last decade in most countries. Neither the quality of life nor our global economy can afford to continue these trends.

Indeed, science, health care and disease are now shared globally. Biomedical research is resource-intensive. Evidence gathered in one country is used in others, sometimes without adequate study. Especially for diseases in which large numbers of participants and locations are needed to answer scientific questions with statistical validity, international studies are essential. In rare diseases, it is impossible to do studies in single countries. An outstanding example is the development of arsenic trioxide for acute promyelocytic leukemia, a treatment discovered in China, studied worldwide and now benefiting patients on every continent. Regardless of economic resources, all countries should participate in joint scientific enterprises to ensure maximal benefit.

The OECD recommendations are designed to facilitate collaboration, leverage existing investments, and enable all nations to improve the health of their citizens and economies, enhancing technological development while prolonging healthier, more productive, lives.

References

The 2012 OECD Recommendation on the Governance of Clinical Trials and its explanatory memorandum can be found at www.oecd.org/sti/sci-tech/oecd-recommendation-governance-of-clinical-trials.pdf

See www.oecd.org/health

The Lancet 2012), The Global Burden of Disease Study 2010, December 13

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (NCPHSBBR) (1979), “The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research”

“The Nuremberg Code”(1949), Trials of War Criminals before the Nuremberg Military Tribunals Under Control Council Law No. 10, Vol. 2, pp. 181–182, US Government Printing Office, Washington

World Medical Association (WMA) (1964/2008), “The Declaration of Helsinki”

©OECD Observer No 294 Q1 2013




Economic data

GDP : +0.5%, Q4 2014
Employment rate: 65.9%, Q4 2014
Annual inflation : 0.57% Feb 2015
Trade : -3.0% exp, -3.7 imp, Q4 2014
Unemployment : 7.022% Feb 2015
More moderate expansion ahead? Composite leading indicators
Updated: 23 Apr 2015

E-Newsletter

Stay up-to-date with the latest news from the OECD by signing up for our e-newsletter :

Twitter feed

Suscribe now

<b>Subscribe now!</b>

To receive your exclusive print editions delivered to you directly


Online edition
Previous editions

Don't miss

  • Africa vs profit shifting African countries heavily rely on the income generated by multinationals’ taxation, which can represent as much as 88% of a country’s tax base. Little wonder Africa is involved in the OECD’s initiative to address tax base erosion caused by profit shifting, known as BEPS. The need to strengthen inter-governmental co-operation to curb cross-border tax losses was reaffirmed at the Africa Tax Administration Forum (ATAF) in Sandton on 21 April 2015.
  • Africa v. profit shifting
  • Rana Plaza
  • Wal-Mart, Other Retailers Sued over Bangladesh Factory Collapse Two years after the April 24, 2013, Bangladeshi factory collapse in the capital of Dhaka, the victims' families filed a lawsuit in U.S. federal court in Washington against Wal-Mart Stores Inc and other U.S.-based companies that sourced out their products from the Rana factory. Read more on Telesur's website.
  • Today, after three years of drought, California is in the midst of a full-blown political and environmental crisis, with restrictions imposed across the state, reports the Financial Times.
  • Lack of water holding back Asian growth In Asia, the world’s most dynamic region with the fastest economic growth, 75% of countries face serious water shortages.
  • Why is the gap between rich and poor growing despite rises in GDP? Do benefits help? Does aid work? (The Guardian)
  • ADB water
  • Greek finance minister Yanis Varoufakis expressed its scepticism towards the Eurozone’s institutions and gave ideas for ways forward. "Greece must become reformable again", Yanis Varoufakis said.
  • Business brief: Israel's water
  • #OECD360: Your country in figures.
  • How to ensure transparency in public procurement? Read Cobus de Swardt's article on OECD Insights.
  • Asia to maintain a strong 6.3% growth rate in 2015 and 2016, according to the Asian Development Bank
  • After three decades of extraordinary economic development, China is shifting to a slower and more sustainable growth path, according to the OECD's latest Economic Survey of China.
  • In pursuit of the American Dream
  • Iceland's strong recovery stems from the good use of its natural resources, the energy sector and tourism according to Peter Dohlman, IMF Mission Chief for Iceland.
  • cyclone
  • Government representatives and experts from around the world are gathering in Japan this week to develop a post-2015 framework for global disaster risk reduction. The World Bank and the Global Facility for Disaster Reduction and Recovery (GFDRR) will share expertise at the conference.
  • Switzerland’s recent moves towards greater tax transparency were welcomed by the Global Forum on Transparency and Exchange of Information for Tax Purposes, based at the OECD, as a boost to international efforts to end tax evasion. Work will continue with Switzerland, notably on implementation, in 2015.
  • Help bridge the gap between business integrity policies & practices:participate in this new OECD survey by clicking on the image.
  • What can we do to promote better literacy skills for all? Read Andreas Schleicher's latest blog on oecdeducationtoday.
  • pisa
  • Secretary General Angel Gurría describes the Programme for International Student Assessment (PISA) as a useful tool to enhance educational systems but states that improving a country's ranking should not be a goal per se. Article in Spanish by El País.
  • [VIDEO] Although many countries have made great progress in narrowing gender gaps in education, new challenges are looming.
  • 5 things you might not know about the state of Amazonas. The World Bank identifies the main colossal challenges Brazil's biggest state is facing.
  • Gender mainstreaming: young French lady working in an engine assembly plant. Women and men in the same boat when it comes to job insecurity. © Raphaël Helle / Signatures / La France VUE D'ICI
  • The Asian Development Bank together with the International Labour Organization challenge the concept of women's work in Asia and the Pacific.
  • Visit the OECD Gender Data Portal. Selected indicators shedding light on gender inequalities in education, employment and entrepreneurship.
  • The 5th Anti-corruption conference for G20 governments and business in Istanbul on 6 March will address how all businesses can play their part in contributing to growth and investment, and can operate with clean hands in a safe environment.
  • Success story. Discover the story of this young Ethiopian woman who launched a successful business in the footwear industry and became a UN Goodwill Ambassador for Entrepreneurship.
  • Transports in Asia. The Asian Development Bank advocates sustainable transport in a continent where vehicle ownership is perceived as a sign of social success.
  • Vote for your favourite photograph! This World Bank #EachDayISee photo contest aims to display visual stories from all over the world through which people express what they would like to see changed and improved.
  • Why is investment so low in the euro area? This short IMF blog post gives you an insight into the causes of the euro-zone's drastic decline in investment.
  • Have your say! The UN wants to know what matters most to you: pick six global issues in the list and send it to the United Nations.
  • Tim Harcourt Video
  • G20 and Australia: Bestselling economist Tim Harcourt speaks to the BBC about how Australia has gone from "Down Under to Down Wonder".
  • Clear air and healthy lungs: how to better tackle air pollution. From New Delhi to Accra, millions of people breathe polluted air. A new report examines the World Bank’s experience working to improve air quality.

Most Popular Articles

Poll

What issue are you most concerned about in 2015?

Euro crisis
Unemployment
Global warming
International conflict
Other

OECD Insights Blog

NOTE: All signed articles in the OECD Observer express the opinions of the authors
and do not necessarily represent the official views of OECD member countries.

All rights reserved. OECD 2015